Nektar Therapeutics
Nektar Therapeutics develops immune‑modulating therapies for autoimmune diseases and oncology. Lead candidates NKTR‑358 and NKTR‑255 are in late‑stage trials, supported by collaborations with Takeda, Roche, Pfizer, and other major pharma partners.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 61
- HQ: San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.